Transcriptomics Signature of Anti Vaccinia Memory B Cells
NCT02556489 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2015-09-30
Summary
Analyse the transcriptomic signature of anti vaccinia memory B cells at a short time after vaccination as compared to the signature already established in long-lived memory B cells.
Conditions
- Healthy
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
lead OTHER_GOV
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-09-30
- Primary Completion
- 2016-09-30
- Completion
- 2016-09-30
More Related Trials
-
Lymphocytes Subpopulation in Cancer Patients
NCT02516371 ·Status: UNKNOWN ·Phase: NA
-
VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
NCT01132859 ·Status: RECRUITING
-
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
NCT04948619 ·Status: RECRUITING ·Phase: PHASE2
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
NCT04871932 ·Status: RECRUITING
-
microRNA Profile in Umbilical Cord Blood NK Cells
NCT00751569 ·Status: UNKNOWN
-
Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients
NCT02565589 ·Status: COMPLETED
-
Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System
NCT04743388 ·Status: UNKNOWN
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Vaccine Response With NT-I7
NCT04054752 ·Status: WITHDRAWN ·Phase: PHASE1
-
Host Immune Response to Novel RNA COVID-19 Vaccination
NCT04784689 ·Status: COMPLETED
-
Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
NCT06842407 ·Status: RECRUITING
-
Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
NCT02739412 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Cognition of Patients Treated With Immunotherapy
NCT03599830 ·Status: COMPLETED ·Phase: NA
-
Immunity to Infection in Healthy Participants and Participants With Cancer
NCT05787964 ·Status: ACTIVE_NOT_RECRUITING
-
Immune Response to the COVID-19 Vaccine
NCT04936997 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PBMC Collection for Production of UCAR T Cells
NCT04963959 ·Status: UNKNOWN ·Phase: NA
-
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
NCT06626269 ·Status: RECRUITING ·Phase: NA
-
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
NCT02880046 ·Status: UNKNOWN
-
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
NCT03827343 ·Status: ACTIVE_NOT_RECRUITING
-
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
NCT04871165 ·Status: UNKNOWN
-
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
NCT04298502 ·Status: UNKNOWN
-
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
NCT01795378 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Neutralizing Power of Serum Antibodies - 2
NCT07085611 ·Status: RECRUITING ·Phase: NA
-
Immuno-Oncology Database and Bioregistry
NCT04656873 ·Status: ACTIVE_NOT_RECRUITING